{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:04:04Z","timestamp":1785683044399,"version":"3.56.0"},"reference-count":177,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Myelofibrosis (MF) is an essential element of primary myelofibrosis, whereas secondary MF may develop in the advanced stages of other myeloid neoplasms, especially polycythemia vera and essential thrombocythemia. Over the last two decades, advances in molecular diagnostic techniques, particularly the integration of next-generation sequencing in clinical laboratories, have revolutionized the diagnosis, classification, and clinical decision making of myelofibrosis. Driver mutations involving JAK2, CALR, and MPL induce hyperactivity in the JAK-STAT signaling pathway, which plays a central role in cell survival and proliferation. Approximately 80% of myelofibrosis cases harbor additional mutations, frequently in the genes responsible for epigenetic regulation and RNA splicing. Detecting these mutations is crucial for diagnosing myeloproliferative neoplasms (MPNs), especially in cases where no mutations are present in the three driver genes (triple-negative MPNs). While fibrosis in the bone marrow results from the disturbance of inflammatory cytokines, it is fundamentally associated with mutation-driven hematopoiesis. The mutation profile and order of acquiring diverse mutations influence the MPN phenotype. Mutation profiling reveals clonal diversity in MF, offering insights into the clonal evolution of neoplastic progression. Prognostic prediction plays a pivotal role in guiding the treatment of myelofibrosis. Mutation profiles and cytogenetic abnormalities have been integrated into advanced prognostic scoring systems and personalized risk stratification for MF. Presently, JAK inhibitors are part of the standard of care for MF, with newer generations developed for enhanced efficacy and reduced adverse effects. However, only a minority of patients have achieved a significant molecular-level response. Clinical trials exploring innovative approaches, such as combining hypomethylation agents that target epigenetic regulators, drugs proven effective in myelodysplastic syndrome, or immune and inflammatory modulators with JAK inhibitors, have demonstrated promising results. These combinations may be more effective in patients with high-risk mutations and complex mutation profiles. Expanding mutation profiling studies with more sensitive and specific molecular methods, as well as sequencing a broader spectrum of genes in clinical patients, may reveal molecular mechanisms in cases currently lacking detectable driver mutations, provide a better understanding of the association between genetic alterations and clinical phenotypes, and offer valuable information to advance personalized treatment protocols to improve long-term survival and eradicate mutant clones with the hope of curing MF.<\/jats:p>","DOI":"10.3390\/cancers16030514","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T06:54:12Z","timestamp":1706165652000},"page":"514","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements"],"prefix":"10.3390","volume":"16","author":[{"given":"Tanvi","family":"Verma","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papadantonakis","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Peker Barclift","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5128-075X","authenticated-orcid":false,"given":"Linsheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and histiocytic\/Dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-018-0453-y","article-title":"Post-ET and post-PV myelofibrosis: Updates on a distinct prognosis from primary myelofibrosis","volume":"13","author":"Passamonti","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/labmed\/lmac074","article-title":"Essential thrombocythemia and post-essential thrombocythemia myelofibrosis: Updates on diagnosis, clinical aspects, and management","volume":"54","author":"Puglianini","year":"2023","journal-title":"Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev-pathol-012615-044454","article-title":"Pathogenesis of myeloproliferative disorders","volume":"11","author":"Nangalia","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"ref_7","first-page":"4510","article-title":"Current status and hotspots evolution in myeloproliferative neoplasm: A bibliometric analysis from 2001 to 2022","volume":"27","author":"Chen","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.leukres.2017.06.004","article-title":"Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease","volume":"60","author":"Barosi","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1182\/blood-2016-01-694182","article-title":"Mutant calreticulin: When a chaperone becomes intrusive","volume":"127","author":"Cazzola","year":"2016","journal-title":"Blood"},{"key":"ref_12","unstructured":"Kanagal-Shamanna, R., Kikkeri, N.N., Sandeep, S.D., Mesa, R., Giraudier, S., Harrison, C.N., and Milojkovic, D. (2023, December 03). Primary Myelofibrosis. WHO Classifications of Tumours Online. Available online: https:\/\/tumourclassification.iarc.who.int\/chaptercontent\/63\/15."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","article-title":"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: Primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable","volume":"143","author":"Kim","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood.2022016846","article-title":"Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms","volume":"141","author":"Pecquet","year":"2023","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-023-00786-x","article-title":"Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis","volume":"13","author":"Guglielmelli","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/ijlh.14185","article-title":"Overt primary myelofibrosis with coexistence of JAK2V617F and MPLW515R driver mutations","volume":"46","author":"Wang","year":"2024","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15330338231154092","DOI":"10.1177\/15330338231154092","article-title":"Genetic and clinical characteristics of patients with Philadelphia-negative myeloproliferative neoplasm carrying concurrent mutations in JAK2V617F, CALR, and MPL","volume":"22","author":"Wang","year":"2023","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3324\/haematol.2020.260448","article-title":"Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing","volume":"106","author":"Thompson","year":"2021","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/hematolrep15020033","article-title":"Additional genetic alterations and clonal evolution of MPNs with double mutations on the MPL gene: Two case reports","volume":"15","author":"Pennisi","year":"2023","journal-title":"Hematol. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Nivarthi","year":"2016","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12032-017-0944-z","article-title":"Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms","volume":"34","author":"Chang","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.3324\/haematol.2022.280917","article-title":"Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis","volume":"107","author":"Lemoine","year":"2022","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2017.139","article-title":"The role of LNK\/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders","volume":"31","author":"Maslah","year":"2017","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/HS9.0000000000000044","article-title":"Clinical utility of next-generation sequencing in the management of myeloproliferative neoplasms: A single-center experience","volume":"2","author":"Alduaij","year":"2018","journal-title":"Hemasphere"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"AACR Project GENIE Consortium (2017). AACR Project GENIE: Powering precision medicine through an international consortium. Cancer Discov., 7, 818\u2013831.","DOI":"10.1158\/2159-8290.CD-17-0151"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102435","DOI":"10.1016\/j.ctrv.2022.102435","article-title":"Impact of molecular profiling on the management of patients with myelofibrosis","volume":"109","author":"Ferrer","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1241912","DOI":"10.3389\/fgene.2023.1241912","article-title":"BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing","volume":"14","year":"2023","journal-title":"Front. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2009.01224.x","article-title":"Conventional cytogenetics in myelofibrosis: Literature review and discussion","volume":"82","author":"Hussein","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ajcp\/aqw222","article-title":"Comparison of the mutational profiles of primary myelofibrosis, polycythemia vera, and essential thrombocytosis","volume":"147","author":"Song","year":"2017","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11899-022-00685-1","article-title":"Molecular pathogenesis of myeloproliferative neoplasms","volume":"17","author":"Rolles","year":"2022","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","article-title":"Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up","volume":"97","author":"Bellosillo","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/gcc.22789","article-title":"Targeted molecular characterization shows differences between primary and secondary myelofibrosis","volume":"59","author":"Courtier","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: A FIM study","volume":"5","author":"Riou","year":"2021","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-023-00829-3","article-title":"Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression","volume":"13","author":"Yan","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Kralovics","year":"2023","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1190305","DOI":"10.3389\/fonc.2023.1190305","article-title":"The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis","volume":"13","author":"Pettersson","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","article-title":"RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features","volume":"4","author":"Coltro","year":"2020","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Reynolds, S.B., Pettit, K., Kandarpa, M., Talpaz, M., and Li, Q. (2023). Exploring the molecular landscape of myelofibrosis, with a focus on Ras and mitogen-activated protein (MAP) kinase signaling. Cancers, 15.","DOI":"10.3390\/cancers15184654"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2021-150191","article-title":"Single-cell multi-omics reveals the genetic, cellular and molecular landscape of TP53 mutated leukemic transformation in MPN","volume":"138","author":"Rahman","year":"2021","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"Kundra","year":"2023","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2020010402","article-title":"Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms","volume":"138","author":"Marcault","year":"2021","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Chifotides, H.T., Verstovsek, S., and Bose, P. (2023). Association of myelofibrosis phenotypes with clinical manifestations, molecular profiles, and treatments. Cancers, 15.","DOI":"10.3390\/cancers15133331"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","article-title":"Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis","volume":"213","author":"Shimizu","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6774","DOI":"10.1038\/s41598-017-07057-3","article-title":"Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations","volume":"7","author":"Nielsen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","article-title":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","volume":"571","author":"Nam","year":"2019","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","article-title":"Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing","volume":"73","author":"Buck","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41375-023-01878-0","article-title":"SRSF2-P95H decreases JAK\/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice","volume":"37","author":"Willekens","year":"2023","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/bloodadvances.2021005867","article-title":"Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition","volume":"6","author":"Maslah","year":"2022","journal-title":"Blood Adv."},{"key":"ref_58","first-page":"2901","article-title":"Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"141","author":"Gagelmann","year":"2023","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2023-189767","article-title":"MPN transformation is characterized by heterogeneous shifts in lineage character","volume":"142","author":"Dilip","year":"2023","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2006-04-017392","article-title":"Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera","volume":"108","author":"Ishii","year":"2006","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Visani, G., Etebari, M., Fuligni, F., Di Guardo, A., Isidori, A., Loscocco, F., Paolini, S., Navari, M., and Piccaluga, P.P. (2023). Use of next generation sequencing to define the origin of primary myelofibrosis. Cancers, 15.","DOI":"10.3390\/cancers15061785"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., and Galinsky, I. (2006). MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030270"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2017-09-806356","article-title":"Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage","volume":"131","author":"Li","year":"2018","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","article-title":"Life histories of myeloproliferative neoplasms inferred from phylogenies","volume":"602","author":"Williams","year":"2022","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2018.03.025","article-title":"Loss of Dnmt3a immortalizes hematopoietic stem cells in vivo","volume":"23","author":"Jeong","year":"2018","journal-title":"Cell Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Streck, A., Kaufmann, T.L., and Schwarz, R.F. (2023). SMITH: Spatially constrained stochastic model for simulation of intra-tumour heterogeneity. Bioinformatics, 39.","DOI":"10.1093\/bioinformatics\/btad102"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2018-06-858597","article-title":"Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms","volume":"132","author":"Sud","year":"2018","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood-2022-164827","article-title":"Jak2V617F reversible activation shows an essential requirement for Jak2V617F in myeloproliferative neoplasms (MPNs)","volume":"140","author":"Dunbar","year":"2022","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/10428199509054751","article-title":"TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders","volume":"20","year":"1995","journal-title":"Leuk. Lymphoma"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3324\/haematol.2019.226332","article-title":"Platelet-derived growth factor receptor \u03b2 activation and regulation in murine myelofibrosis","volume":"105","author":"Kramer","year":"2020","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/path.1744","article-title":"Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders","volume":"205","author":"Bock","year":"2005","journal-title":"J. Pathol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2005.05573.x","article-title":"Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin","volume":"130","author":"Bock","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood.2022018859","article-title":"Two to tango! IL-13 and TGF-\u03b2 drive myelofibrosis","volume":"140","author":"Jutzi","year":"2022","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1182\/blood.2022017326","article-title":"IL-13\/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms","volume":"140","author":"Bezavada","year":"2022","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12291-016-0576-7","article-title":"Lysyl oxidase: Its diversity in health and diseases","volume":"32","author":"Kumari","year":"2017","journal-title":"Indian J. Clin. Biochem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2012-02-402594","article-title":"Megakaryocyte pathology and bone marrow fibrosis: The lysyl oxidase connection","volume":"120","author":"Papadantonakis","year":"2012","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.23409","article-title":"The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms","volume":"88","author":"Tadmor","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_83","first-page":"23","article-title":"Lysyl oxidase inhibition in primary myelofibrosis: A renewed strategy","volume":"1","author":"Piasecki","year":"2020","journal-title":"Arch. Stem Cell Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41375-020-0880-3","article-title":"Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice","volume":"35","author":"Ozono","year":"2021","journal-title":"Leukemia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41563-022-01293-3","article-title":"Mechanical checkpoint regulates monocyte differentiation in fibrotic niches","volume":"21","author":"Vining","year":"2022","journal-title":"Nat. Mater."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12967-023-04393-z","article-title":"Fibrosis and bone marrow: Understanding causation and pathobiology","volume":"21","author":"Ghosh","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.exphem.2009.07.005","article-title":"JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis","volume":"37","author":"Hussein","year":"2009","journal-title":"Exp. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/ajcp\/aqac173","article-title":"Comparison of clinical and molecular features between patients with essential thrombocythemia and early\/prefibrotic primary myelofibrosis presenting with thrombocytosis in Taiwan","volume":"159","author":"Kuo","year":"2023","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2021-149226","article-title":"High throughput single-cell simultaneous genotyping and chromatin accessibility reveals genotype to phenotype relationship in human myeloproliferation","volume":"138","author":"Myers","year":"2021","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Myers, R.M., Izzo, F., Kottapalli, S., Prieto, T., Dunbar, A., Bowman, R.L., Mimitou, E.P., Stahl, M., El Ghaity-Beckley, S., and Arandela, J. (2022). Integrated single-cell genotyping and chromatin accessibility charts JAK2V617F human hematopoietic differentiation. bioRxiv.","DOI":"10.1101\/2022.05.11.491515"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","article-title":"Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets","volume":"78","author":"Psaila","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1792037","DOI":"10.1080\/2162402X.2020.1792037","article-title":"Surface-exposed and soluble calreticulin: Conflicting biomarkers for cancer prognosis","volume":"9","author":"Kepp","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41375-023-01848-6","article-title":"Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities","volume":"37","author":"Pabst","year":"2023","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1600-0609.2010.01548.x","article-title":"The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera","volume":"86","author":"Abdulkarim","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Chen, M., Zhang, C., Hu, Z., Li, Z., Li, M., Wu, L., Zhou, M., and Liang, D. (2021). CRISPR\/Cas12a-based ultrasensitive and rapid detection of JAK2 V617F somatic mutation in myeloproliferative neoplasms. Biosensors, 11.","DOI":"10.3390\/bios11080247"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-1-60761-947-5_2","article-title":"Conformation sensitive gel electrophoresis","volume":"688","author":"Hill","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/ijlh.13628","article-title":"Conformation sensitive gel electrophoresis for the detection of calreticulin mutations in BCR-ABL1-negative myeloproliferative neoplasms","volume":"43","author":"Zakaria","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Krishnamurthy, K., Chai, J., Wang, Y., Naeem, R., and Goldstein, D.Y. (2023). Pitfalls of using polymerase chain reaction-based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile!. Am. J. Clin. Pathol., aqad122.","DOI":"10.1093\/ajcp\/aqad122"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/ijlh.13282","article-title":"Pitfalls in CALR exon 9 mutation detection: A single-center experience in 571 positive patients","volume":"42","author":"Verger","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1182\/blood.2019002943","article-title":"MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages","volume":"136","author":"Nienhold","year":"2020","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jmoldx.2022.08.006","article-title":"Optimizing insertion and deletion detection using next-generation sequencing in the clinical laboratory","volume":"24","author":"Craven","year":"2022","journal-title":"J. Mol. Diagn."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/omi.2023.0059","article-title":"Whole exome sequencing reveals novel variants in unexplained erythrocytosis","volume":"27","author":"Khurana","year":"2023","journal-title":"OMICS J. Integr. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41375-023-01857-5","article-title":"Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies","volume":"37","author":"Sakuma","year":"2023","journal-title":"Leukemia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.27136","article-title":"The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70\/plus\/plus v2.0) for primary myelofibrosis","volume":"99","author":"Loscocco","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1224590","DOI":"10.3389\/fonc.2023.1224590","article-title":"The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease\u2019s phenotype","volume":"13","author":"Sobieralski","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.3324\/haematol.2015.138958","article-title":"Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome","volume":"101","author":"Asp","year":"2016","journal-title":"Haematologica"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"12539","DOI":"10.1038\/s41598-023-39077-7","article-title":"Systemic inflammatory indices for predicting prognosis of myelofibrosis","volume":"13","author":"Ersal","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/blood.2023021218","article-title":"How I treat transplant-eligible patients with myelofibrosis","volume":"142","author":"Wolschke","year":"2023","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2017.157","article-title":"Impact of molecular residual disease post allografting in myelofibrosis patients","volume":"52","author":"Wolschke","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-023-01471-z","article-title":"Ten years of treatment with ruxolitinib for myelofibrosis: A review of safety","volume":"16","author":"Verstovsek","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/10428194.2023.2196593","article-title":"Ten years after ruxolitinib approval for myelofibrosis: A review of clinical efficacy","volume":"64","author":"Pemmaraju","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e982","DOI":"10.1097\/HS9.0000000000000982","article-title":"Is treatment for cytopenic myelofibrosis still an unmet clinical need?","volume":"7","author":"Caduc","year":"2023","journal-title":"Hemasphere"},{"key":"ref_123","first-page":"862","article-title":"FDA approves fourth JAK inhibitor for myelofibrosis","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/leu.2016.45","article-title":"JAK2(V617F) allele burden \u226550% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy","volume":"30","author":"Barosi","year":"2016","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1002\/cncr.34986","article-title":"New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-XL\/BCL-2 inhibition with navitoclax","volume":"129","author":"Pemmaraju","year":"2023","journal-title":"Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/bloodadvances.2022007230","article-title":"Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story","volume":"6","author":"Barosi","year":"2022","journal-title":"Blood Adv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.3324\/haematol.2022.282612","article-title":"Momelotinib (JAK1\/JAK2\/ACVR1 inhibitor): Mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis","volume":"108","author":"Tefferi","year":"2023","journal-title":"Haematologica"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv."},{"key":"ref_133","first-page":"5929","article-title":"Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden","volume":"4","author":"Tremblay","year":"2020","journal-title":"Blood Adv."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3324\/haematol.2016.148924","article-title":"A phase 1\/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis","volume":"102","author":"Gupta","year":"2017","journal-title":"Haematologica"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2017009530","article-title":"Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1\/2 inhibitor therapy","volume":"1","author":"Spiegel","year":"2017","journal-title":"Blood Adv."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS-pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1038\/s41375-023-02027-3","article-title":"RAS-pathway mutations are common in patients with ruxolitinib refractory\/intolerant myelofibrosis: Molecular analysis of the PAC203 cohort","volume":"37","author":"Taylor","year":"2023","journal-title":"Leukemia"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-018-0067-6","article-title":"Momelotinib therapy for myelofibrosis: A 7-year follow-up","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1097\/HS9.0000000000000757","article-title":"A phase 1b dose-finding study of panobinostat and ruxolitinib in myelofibrosis","volume":"6","author":"Harrison","year":"2022","journal-title":"Hemasphere"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/HS9.0000000000000054","article-title":"LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone","volume":"2","author":"Jutzi","year":"2018","journal-title":"Hemasphere"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-023-01446-0","article-title":"Novel agents and evolving strategies in myelofibrotive neoplasm: An update from 2022 ASH annual conference","volume":"16","author":"Wang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Gill, H. (2022). Lysine-Specific Demethylase 1 (LSD1\/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells, 11.","DOI":"10.3390\/cells11132107"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Pettit, K. (2023, December 10). A Phase 2 Study of the LSD1 Inhibitor IMG7289 (Bomedemstat) for the Treatment of Advanced Myelofibrosis. ASH. Available online: https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper136001.html.","DOI":"10.1182\/blood-2019-123244"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.23.00833","article-title":"Myelofibrosis: In search for BETter targeted therapies","volume":"41","author":"Palumbo","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/s41375-021-01405-z","article-title":"Paradigm shift: Combination BET and JAK inhibition in myelofibrosis","volume":"35","author":"Mascarenhas","year":"2021","journal-title":"Leukemia"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2217\/fon-2022-0484","article-title":"Phase III MANIFEST-2: Pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis","volume":"18","author":"Harrison","year":"2022","journal-title":"Future Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1038\/s41467-023-42101-z","article-title":"Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis","volume":"14","author":"Wildschut","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1158\/2159-8290.CD-20-0026","article-title":"PRMT5 inhibition modulates E2F1 methylation and gene-regulatory networks leading to therapeutic efficacy in JAK2V617F-mutant MPN","volume":"10","author":"Pastore","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1182\/blood-2021-150938","article-title":"A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with myeloid malignancies","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2217\/fon-2022-0235","article-title":"Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design","volume":"18","author":"Mascarenhas","year":"2022","journal-title":"Future Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1277453","DOI":"10.3389\/fonc.2023.1277453","article-title":"The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling","volume":"13","author":"Olschok","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood-2023-173509","article-title":"Transform-1: A randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis","volume":"142","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2023-179141","article-title":"Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study","volume":"142","author":"Rampal","year":"2023","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2022-164678","article-title":"Molecularly targeted combination therapy for advanced phase myeloproliferative neoplasm: MPN-RC 119","volume":"140","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: New evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: Pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"683401","DOI":"10.3389\/fimmu.2021.683401","article-title":"Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms","volume":"12","author":"Fisher","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MOH.0000000000000778","article-title":"Inflammation and bone marrow fibrosis: Novel immunotherapeutic targets","volume":"30","author":"Calledda","year":"2023","journal-title":"Curr. Opin. Hematol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: Targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2016","journal-title":"Leukemia"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2021010986","article-title":"Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN\u03b1 in myeloproliferative neoplasms","volume":"138","author":"Mosca","year":"2021","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/bloodadvances.2021004856","article-title":"Genomic profiling of a randomized trial of interferon-\u03b1 vs hydroxyurea in MPN reveals mutation-specific responses","volume":"6","author":"Knudsen","year":"2022","journal-title":"Blood Adv."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.2022017416","article-title":"Biology and therapeutic targeting of molecular mechanisms in MPNs","volume":"141","author":"How","year":"2023","journal-title":"Blood"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood.2020005563","article-title":"JAK2-V617F and interferon-\u03b1 induce megakaryocyte-biased stem cells characterized by decreased long-term functionality","volume":"137","author":"Rao","year":"2021","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/cncr.30679","article-title":"The effect of initial molecular profile on response to recombinant interferon-\u03b1 (rIFN\u03b1) treatment in early myelofibrosis","volume":"123","author":"Silver","year":"2017","journal-title":"Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1182\/blood-2022-167002","article-title":"Combination of 5-Azacytidine and Pegifna is able to overcome resistance in JAK2-V617F positive MPN with loss of Dnmt3a","volume":"140","author":"Lock","year":"2022","journal-title":"Blood"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2022-156389","article-title":"Final results of Ruxopeg, a phase 1\/2 adaptive randomized trial of ruxolitinib (rux) and pegylated interferon alpha (ifna) 2a in patients with myelofibrosis (MF)","volume":"140","author":"Kiladjian","year":"2022","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e956","DOI":"10.1016\/j.clml.2020.07.006","article-title":"Retrospective analysis of the clinical use and benefit of lenalidomide and thalidomide in myelofibrosis","volume":"20","author":"Talati","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: A multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41375-023-01861-9","article-title":"Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives","volume":"37","author":"Barosi","year":"2023","journal-title":"Leukemia"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-020-00368-1","article-title":"A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis","volume":"10","author":"Carobbio","year":"2020","journal-title":"Blood Cancer J."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/3\/514\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:48:56Z","timestamp":1760104136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/3\/514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":177,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["cancers16030514"],"URL":"https:\/\/doi.org\/10.3390\/cancers16030514","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}